Elie Ata
Family Medicine · Lawrence, MANPI 1659801520
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Bayer at 42.7% of the total. 2025 is the largest year on record at $3,427, more than ten times the $26 reported in 2021. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $34.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$3K
- AbbVie$1K
- AstraZeneca$601
- Novo Nordisk$480
- Novartis$439
- Amgen$404
- plus $1K from 24 others
What the payments were for
- Consulting fees$2,91739%
- Food & beverage$4,45160%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 9 | $3,194 |
| AbbVie | 55 | $1,008 |
| AstraZeneca | 26 | $601 |
| Novo Nordisk | 20 | $480 |
| Novartis | 24 | $439 |
| Amgen | 19 | $404 |
| Pfizer | 9 | $187 |
| Inspire Medical Systems, Inc. | 8 | $153 |
| Lilly USA, LLC | 7 | $139 |
| Astellas Pharma US Inc | 5 | $112 |
| Johnson & Johnson | 3 | $84 |
| Abbott | 4 | $69 |
| Merck | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Shield Therapeutics Inc | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $50 |
| Exact Sciences | 2 | $46 |
| Aspira Women's Health Inc | 1 | $41 |
| Scpharmaceuticals Inc. | 1 | $39 |
| Dexcom, Inc. | 1 | $37 |
| Vertex | 1 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Indivior Inc. | 1 | $21 |
| Pear Therapeutics (US), Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Qiagen, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,476 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $85,330 |
| JardianceEmpagliflozin | 45 | $67,783 |
| TrulicityDulaglutide | 50 | $56,308 |
| FarxigaDapagliflozin Propanediol | 34 | $40,558 |
| OzempicSemaglutide | 30 | $31,517 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $19,756 |
| MounjaroTirzepatide | 17 | $18,826 |
| LinzessLinaclotide | 19 | $18,272 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $17,108 |
| EntrestoSacubitril/Valsartan | 24 | $16,877 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,820 |
| Atorvastatin Calcium | 343 | $3,946 |
| Gabapentin | 140 | $3,048 |
| Metoprolol Succinate | 172 | $2,614 |
| Omeprazole | 116 | $2,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $187 | $85,33073 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $139 | $75,13467 claims |
| Boehringer IngelheimJardiance | $16 | $67,78345 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $601 | $57,66759 claims |
| Novo NordiskOzempic | $480 | $31,51730 claims |
| AbbVieLinzess | $1,008 | $18,27219 claims |
| NovartisEntresto | $439 | $16,87724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Lawrence
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
- Karen HuntLawrence$8K
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.